
Clinical Research Grant

The Clinical Research Grant supports innovative haemostatic research on non-interventional observational studies focusing on patient outcomes, quality of life and social impact.

The maximum grant for up to one year is € 70,000.

Areas of interest include, *but are not limited to*:

- Treatment options, outcome measures, and compliance
- Epidemiology of inhibitor development, including factors relevant to susceptibility
- Inhibitor management issues (e.g. with focus on tolerization/immunomodulation)
- Health economic outcomes
- Quality of care related areas including patients' quality of life, unmet needs, and psychosocial issues associated with the disease
- Diagnosis and treatment of von Willebrand disease and platelet disorders
- Investigation of joint health; prophylaxis and improvement of long-term joint health outcomes

In order to maintain a focus on the treatment of haemophilia and other rare bleeding disorders, *Access to Insight* clinical research grants will not support research focused on:

- Pathophysiology, diagnosis, and treatment of blood transmitted diseases
- Thrombotic disorders
- Products or technologies licensed or patented by competitors of Novo Nordisk

Applicants should be health care professionals providing care for haemophilia and rare bleeding disorders patients, including nurses, physiotherapists, and psychologists.

It is assumed that a maximum of 20% of the total grant can be assigned to the candidate's institute as overhead costs.

The quality of the project idea is the main criterion for the proposal evaluation.

The conditions of the Access to Insight programme require that any additional funding for the same project from other sources (e.g. WFH, ISTH-SSC) be declared to both funding sources. We appreciate grant recipients' cooperation in this regard.

[Download or upload your application form here.](#)

[Please click here for more information about the application review process.](#)

Timeline

